Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Lowered by Wall Street Zen

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

ARTV has been the subject of several other reports. TD Cowen downgraded shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Needham & Company LLC downgraded Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Monday, October 19th. Jefferies Financial Group lowered Artiva Biotherapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Thursday, October 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $40.00 price objective on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $24.80.

Get Our Latest Stock Report on Artiva Biotherapeutics

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $4.01 on Friday. The company has a market cap of $198.21 million, a P/E ratio of -1.35 and a beta of 2.68. The stock has a 50 day simple moving average of $6.66 and a two-hundred day simple moving average of $7.93. Artiva Biotherapeutics has a fifty-two week low of $2.96 and a fifty-two week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01). On average, research analysts predict that Artiva Biotherapeutics will post -2.74 earnings per share for the current year.

Insider Buying and Selling at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 61,696 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $6.84, for a total value of $422,000.64. Following the transaction, the chief executive officer directly owned 1,543,069 shares of the company’s stock, valued at approximately $10,554,591.96. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jennifer Bush sold 8,370 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $6.84, for a total transaction of $57,250.80. Following the completion of the transaction, the chief operating officer directly owned 366,159 shares in the company, valued at approximately $2,504,527.56. The trade was a 2.23% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 137,048 shares of company stock valued at $1,086,167 over the last ninety days. 1.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Empowered Funds LLC bought a new position in Artiva Biotherapeutics during the 3rd quarter valued at $245,000. State Street Corp grew its stake in shares of Artiva Biotherapeutics by 2.5% in the 3rd quarter. State Street Corp now owns 339,761 shares of the company’s stock worth $2,419,000 after acquiring an additional 8,233 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth $144,000. Spark Investment Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth $160,000. Finally, Alyeska Investment Group L.P. grew its stake in shares of Artiva Biotherapeutics by 173.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after acquiring an additional 173,615 shares in the last quarter.

About Artiva Biotherapeutics

(Get Free Report)

Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company’s lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies.

Further Reading

Analyst Recommendations for Artiva Biotherapeutics (NASDAQ:ARTV)

Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.